Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

ELV vs DBVT vs UNH vs ALKS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ELV
Elevance Health Inc.

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$81.37B
5Y Perf.+27.4%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1721.78T
5Y Perf.-58.6%
UNH
UnitedHealth Group Incorporated

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$333.37B
5Y Perf.+20.5%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.89B
5Y Perf.+115.9%

ELV vs DBVT vs UNH vs ALKS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ELV logoELV
DBVT logoDBVT
UNH logoUNH
ALKS logoALKS
IndustryMedical - Healthcare PlansBiotechnologyMedical - Healthcare PlansBiotechnology
Market Cap$81.37B$1721.78T$333.37B$5.89B
Revenue (TTM)$200.41B$0.00$449.71B$1.56B
Net Income (TTM)$5.24B$-168M$12.04B$153M
Gross Margin23.2%18.8%65.4%
Operating Margin3.8%4.2%12.3%
Forward P/E14.0x20.1x24.7x
Total Debt$33.23B$22M$78.39B$70M
Cash & Equiv.$9.49B$194M$24.36B$1.12B

ELV vs DBVT vs UNH vs ALKSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ELV
DBVT
UNH
ALKS
StockMay 20May 26Return
Elevance Health Inc. (ELV)100127.4+27.4%
DBV Technologies S.… (DBVT)10041.4-58.6%
UnitedHealth Group … (UNH)100120.5+20.5%
Alkermes plc (ALKS)100215.9+115.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: ELV vs DBVT vs UNH vs ALKS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ELV leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Alkermes plc is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. DBVT and UNH also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ELV
Elevance Health Inc.
The Insurance Pick

ELV carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.

  • Rev growth 12.6%, EPS growth -2.2%, 3Y rev CAGR 8.3%
  • Lower volatility, beta 0.46, Low D/E 75.5%, current ratio 1.24x
  • Beta 0.46, yield 1.8%, current ratio 1.24x
  • 12.6% revenue growth vs DBVT's -100.0%
Best for: growth exposure and sleep-well-at-night
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the clearest fit if your priority is momentum.

  • +114.1% vs ELV's -7.8%
Best for: momentum
UNH
UnitedHealth Group Incorporated
The Insurance Pick

UNH is the clearest fit if your priority is income & stability and long-term compounding.

  • Dividend streak 25 yrs, beta 0.59, yield 2.4%
  • 220.3% 10Y total return vs ELV's 206.0%
  • 2.4% yield, 25-year raise streak, vs ELV's 1.8%, (2 stocks pay no dividend)
Best for: income & stability and long-term compounding
ALKS
Alkermes plc
The Quality Compounder

ALKS is the #2 pick in this set and the best alternative if quality and efficiency is your priority.

  • 9.8% margin vs DBVT's 0.3%
  • 5.4% ROA vs DBVT's -89.0%
Best for: quality and efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthELV logoELV12.6% revenue growth vs DBVT's -100.0%
ValueELV logoELVLower P/E (14.0x vs 20.1x)
Quality / MarginsALKS logoALKS9.8% margin vs DBVT's 0.3%
Stability / SafetyELV logoELVBeta 0.46 vs DBVT's 1.26
DividendsUNH logoUNH2.4% yield, 25-year raise streak, vs ELV's 1.8%, (2 stocks pay no dividend)
Momentum (1Y)DBVT logoDBVT+114.1% vs ELV's -7.8%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

ELV vs DBVT vs UNH vs ALKS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ELVElevance Health Inc.
FY 2025
Health Benefits Segment
84.8%$167.1B
Carelon Services Segment
36.4%$71.7B
Segment Eliminations
-21.1%$-41,689,000,000
DBVTDBV Technologies S.A.

Segment breakdown not available.

UNHUnitedHealth Group Incorporated
FY 2025
Unitedhealthcare
94.4%$332.4B
Optumhealth
5.6%$19.8B
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M

ELV vs DBVT vs UNH vs ALKS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGUNH

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

UNH and DBVT operate at a comparable scale, with $449.7B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to ELV's 2.6%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plc
RevenueTrailing 12 months$200.4B$0$449.7B$1.6B
EBITDAEarnings before interest/tax$8.9B-$112M$23.2B$212M
Net IncomeAfter-tax profit$5.2B-$168M$12.0B$153M
Free Cash FlowCash after capex$6.5B-$151M$19.7B$392M
Gross MarginGross profit ÷ Revenue+23.2%+18.8%+65.4%
Operating MarginEBIT ÷ Revenue+3.8%+4.2%+12.3%
Net MarginNet income ÷ Revenue+2.6%+2.7%+9.8%
FCF MarginFCF ÷ Revenue+3.2%+4.4%+25.1%
Rev. Growth (YoY)Latest quarter vs prior year+2.6%+2.0%+28.2%
EPS Growth (YoY)Latest quarter vs prior year-16.8%+91.5%+0.7%-4.1%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

ELV leads this category, winning 3 of 6 comparable metrics.

At 14.9x trailing earnings, ELV trades at a 46% valuation discount to UNH's 27.8x P/E. On an enterprise value basis, ELV's 10.9x EV/EBITDA is more attractive than ALKS's 17.2x.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plc
Market CapShares × price$81.4B$1721.78T$333.4B$5.9B
Enterprise ValueMkt cap + debt − cash$105.1B$1721.78T$387.4B$4.8B
Trailing P/EPrice ÷ TTM EPS14.92x-0.76x27.76x24.70x
Forward P/EPrice ÷ next-FY EPS est.14.00x20.06x
PEG RatioP/E ÷ EPS growth rate2.16x
EV / EBITDAEnterprise value multiple10.88x16.61x17.20x
Price / SalesMarket cap ÷ Revenue0.41x0.74x3.99x
Price / BookPrice ÷ Book value/share1.89x0.66x3.29x3.28x
Price / FCFMarket cap ÷ FCF25.64x20.74x12.25x
ELV leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 7 of 9 comparable metrics.

ELV delivers a 11.9% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to UNH's 0.77x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plc
ROE (TTM)Return on equity+11.9%-130.2%+11.5%+8.8%
ROA (TTM)Return on assets+4.3%-89.0%+3.9%+5.4%
ROICReturn on invested capital+9.1%+9.2%+18.9%
ROCEReturn on capital employed+8.2%-145.7%+9.7%+14.2%
Piotroski ScoreFundamental quality 0–96467
Debt / EquityFinancial leverage0.75x0.13x0.77x0.04x
Net DebtTotal debt minus cash$23.7B-$172M$54.0B-$1.0B
Cash & Equiv.Liquid assets$9.5B$194M$24.4B$1.1B
Total DebtShort + long-term debt$33.2B$22M$78.4B$70M
Interest CoverageEBIT ÷ Interest expense5.39x-189.82x4.71x32.30x
ALKS leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DBVT leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,047 today (with dividends reinvested), compared to $3,344 for DBVT. Over the past 12 months, DBVT leads with a +114.1% total return vs ELV's -7.8%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.4% vs UNH's -7.3% — a key indicator of consistent wealth creation.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plc
YTD ReturnYear-to-date+6.3%+5.5%+9.8%+25.0%
1-Year ReturnPast 12 months-7.8%+114.1%-4.7%+16.3%
3-Year ReturnCumulative with dividends-15.3%+20.4%-20.4%+14.3%
5-Year ReturnCumulative with dividends+4.0%-66.6%-2.5%+60.5%
10-Year ReturnCumulative with dividends+206.0%-86.8%+220.3%-7.7%
CAGR (3Y)Annualised 3-year return-5.4%+6.4%-7.3%+4.5%
DBVT leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ELV and ALKS each lead in 1 of 2 comparable metrics.

ELV is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.5% from its 52-week high vs DBVT's 76.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plc
Beta (5Y)Sensitivity to S&P 5000.46x1.26x0.59x1.06x
52-Week HighHighest price in past year$424.24$26.18$404.72$36.60
52-Week LowLowest price in past year$273.71$7.53$234.60$25.17
% of 52W HighCurrent price vs 52-week peak+88.3%+76.8%+90.7%+96.5%
RSI (14)Momentum oscillator 0–10073.443.874.566.6
Avg Volume (50D)Average daily shares traded1.9M253K8.1M2.3M
Evenly matched — ELV and ALKS each lead in 1 of 2 comparable metrics.

Analyst Outlook

UNH leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: ELV as "Buy", DBVT as "Buy", UNH as "Buy", ALKS as "Buy". Consensus price targets imply 130.5% upside for DBVT (target: $46) vs 2.0% for ELV (target: $382). For income investors, UNH offers the higher dividend yield at 2.37% vs ELV's 1.84%.

MetricELV logoELVElevance Health I…DBVT logoDBVTDBV Technologies …UNH logoUNHUnitedHealth Grou…ALKS logoALKSAlkermes plc
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$382.38$46.33$385.43$44.00
# AnalystsCovering analysts37155228
Dividend YieldAnnual dividend ÷ price+1.8%+2.4%
Dividend StreakConsecutive years of raises150250
Dividend / ShareAnnual DPS$6.89$8.70
Buyback YieldShare repurchases ÷ mkt cap+3.2%0.0%+1.7%+0.5%
UNH leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ELV leads in 1 (Valuation Metrics). 1 tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

ELV vs DBVT vs UNH vs ALKS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ELV or DBVT or UNH or ALKS a better buy right now?

For growth investors, Elevance Health Inc.

(ELV) is the stronger pick with 12. 6% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Elevance Health Inc. (ELV) offers the better valuation at 14. 9x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Elevance Health Inc. (ELV) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ELV or DBVT or UNH or ALKS?

On trailing P/E, Elevance Health Inc.

(ELV) is the cheapest at 14. 9x versus UnitedHealth Group Incorporated at 27. 8x. On forward P/E, Elevance Health Inc. is actually cheaper at 14. 0x.

03

Which is the better long-term investment — ELV or DBVT or UNH or ALKS?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

5%, compared to -66. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: UNH returned +220. 3% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ELV or DBVT or UNH or ALKS?

By beta (market sensitivity over 5 years), Elevance Health Inc.

(ELV) is the lower-risk stock at 0. 46β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 172% more volatile than ELV relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 77% for UnitedHealth Group Incorporated — giving it more financial flexibility in a downturn.

05

Which is growing faster — ELV or DBVT or UNH or ALKS?

By revenue growth (latest reported year), Elevance Health Inc.

(ELV) is pulling ahead at 12. 6% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Elevance Health Inc. grew EPS -2. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, UNH leads at 11. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ELV or DBVT or UNH or ALKS?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ELV or DBVT or UNH or ALKS more undervalued right now?

On forward earnings alone, Elevance Health Inc.

(ELV) trades at 14. 0x forward P/E versus 20. 1x for UnitedHealth Group Incorporated — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 130. 5% to $46. 33.

08

Which pays a better dividend — ELV or DBVT or UNH or ALKS?

In this comparison, UNH (2.

4% yield), ELV (1. 8% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is ELV or DBVT or UNH or ALKS better for a retirement portfolio?

For long-horizon retirement investors, Elevance Health Inc.

(ELV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46), 1. 8% yield, +206. 0% 10Y return). Both have compounded well over 10 years (ELV: +206. 0%, DBVT: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ELV and DBVT and UNH and ALKS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELV is a mid-cap deep-value stock; DBVT is a mega-cap quality compounder stock; UNH is a large-cap quality compounder stock; ALKS is a small-cap quality compounder stock. ELV, UNH pay a dividend while DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ELV

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 13%
  • Dividend Yield > 0.7%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

UNH

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Dividend Yield > 0.9%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.